Skip to main content

Table 3 ORs and 95 % CIs for selected NHL histological types by HCV RNA/HBsAg positivity. Italy, 1999–2014

From: Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy

  Allc HCV-RNA+   Alld HBsAg+  
N N (%) OR (95 % CI)a,e N N (%) OR (95 % CI)a,f
Controls 1002 35 (3.5) 1b 997 17 (1.7) 1b
NHL cases 569 63 (11.1)   570 21 (3.7)  
 B-cell lymphomas 512 60 (11.7) 3.71 (2.37–5.81) 513 20 (3.9) 2.11 (1.07–4.15)
   DLBCL 289 37 (12.8) 4.08 (2.46–6.76) 290 15 (5.2) 2.69 (1.30–5.59)
   Burkitt 14 2 (14.3) 4.36 (0.82–23.26) 14 0 (0.0)  
   Follicular 103 1 (1.0) 0.38 (0.05–2.85) 103 4 (3.9) 1.96 (0.61–6.29)
   Mantle cell 14 0 (0.0)   14 0 (0.0)  
   Marginal zone 33 9 (27.3) 8.62 (3.43–21.69) 33 0 (0.0)  
   Lymphoplasmacytic 14 4 (28.6) 8.43 (2.26–31.52) 14 0 (0.0)  
   Other B-cell lymphomas 10 0 (0.0)   10 0 (0.0)  
   SLL/CLL 35 7 (20.0) 7. 96 (2.95–21.48) 35 1 (2.9) 1.18 (0.14–10.05)
 T-cell lymphomas 37 2 (5.4) 1.68 (0.37–7.69) 37 0 (0.0)  
 Other 2 0 (0.0)   2 0 (0.0)  
 NOS 18 1 (5.6) 1.73 (0.20–15.01) 18 1 (5.5) 2.58 (0.28–23.84)
  1. NHL non-Hodgkin lymphoma, OR odds ratio, CI confidence interval, DLBCL diffuse large B-cell lymphoma, SLL small lymphocytic lymphoma, CLL chronic lymphocytic leukemia, NOS not otherwise specified; aEstimated using unconditional logistic regression models adjusted for gender, age, study center, years of education, and place of birth; bReference category. cCases and controls with positive anti-HCV test and without available information on HCV-RNA were excluded; dCases and controls without available information on HBV markers were excluded; eReference category was anti-HCV-; fReference category was HBsAg-/anti-HBs-/anti-HBc-